LeMaitre Vascular enters the post-earnings stretch with one of the more dramatic single-session shifts in options sentiment seen all year — the stock's put/call ratio collapsed from above 6 to 1.84 on August 4, the day results landed, a move three standard deviations below its 20-day average of 4.96.
That options swing is the standout this week. For most of the past month, put/call readings had been running well above 5, reflecting heavy demand for downside protection ahead of the print. The single-day drop to 1.84 — close to the 52-week low of 0.21 — marks a near-complete reversal in hedging posture. Calls are now dominating flow for the first time in weeks. The shift suggests the earnings release resolved a material overhang rather than creating a new one.
The broader positioning picture looks comfortable rather than stressed. Short interest runs at 6.5% of free float — meaningful, but easing. It slipped roughly 1.5% on the week to approximately 1.48 million shares, after building steadily through July from below 1.3 million in late June. That month-long accumulation of shorts — a 16.5% rise — now appears to be unwinding post-print. Borrow conditions reinforce the relaxed tone: cost-to-borrow is 0.43%, down 15% over the past month, and availability holds around 324% — well into the range where supply is plentiful and no squeeze pressure exists. The short score has drifted from the mid-55s to just above 54, consistent with a positioning that is moderately bearish but not conviction-heavy.
The Street sits in a split stance. The consensus is "hold," with five hold-equivalent ratings against one outperform and two market outperform ratings. The mean price target of $117 implies roughly 11% upside from $105.78, though Wells Fargo this morning cut its target from $104 to $94 while keeping an Equal-Weight rating — the only post-earnings analyst action so far, and notable as it now sits well below where the stock is trading. Barrington and Citizens carry targets of $120 and $127 respectively, and neither has updated since May. Bulls point to double-digit organic revenue growth, expanding margins, and a growing biologics portfolio. Bears flag reliance on vascular devices for the bulk of revenue and limited US pricing flexibility. At a trailing P/E near 32 and EV/EBITDA of 22, the valuation is not cheap for a small-cap medical device name, though both multiples have eased slightly over the past 30 days.
Among correlated peers, the picture is mixed. INSP surged 23% on the day and 23% on the week — a strong individual-name move rather than sector-wide momentum. ENOV added 4.5% on the week while GMED and IDXX were broadly flat to slightly positive. LMAT's 3.4% weekly gain sits in the middle of that range, suggesting the stock moved on its own fundamentals rather than being carried by sector flows.
Institutional ownership adds a layer of stability. BlackRock holds nearly 14% of shares. Founder and CEO George LeMaitre retains 6.4%, though recent insider data through early May shows him and other executives selling into strength — including over $6 million in CEO sales in early March and a further $5 million in early May. The net 90-day insider figure reflects those outflows. None of it looks unusual for a founder monetising at elevated prices, but it is worth noting the pattern.
With the next earnings event not until November 5, the question for the coming weeks is whether the sharp options reset holds — or whether put demand rebuilds as the post-earnings clarity fades.
See the live data behind this article on ORTEX.
Open LMAT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
